Nymox director James Robinson continues to add to his significant holding

Posted on by

Nymox Pharmaceutical Corp {NASDAQ: NYMX} Director James George Robinson continued his spate of recent purchases by buying another 20,000 shares in the company.

Robinson is showing huge confidence by continuing to buy in the market in a series of purchases, and now holds a significant investment in US$ terms in the company.

 

Comment

 

Whilst it’s sadly rare to see management investing much in their own companies, in the market at prevailing prices, George Robinson’s support of NYMOX in recent months just has to be admired and respected.

Given the current market volatility, and various international tensions, and with Wall St. falling from recent highs under concerns for the US economy and other issues, Robinson’s support here is quite incredible, in my view.

A fine example of a director putting his money where his mouth is!

 

 

Nymox Pharmaceutical Corp {NASDAQ: NYMX} Director James George Robinson purchased 20,000 shares of the business’s stock in a transaction on Tuesday, January 12th, 2016.

 

The stock was bought at an average cost of $2.44 per share, for a total transaction of $48,800.00. Following the purchase, the director now owns 2,657,550 shares of the company’s stock, valued at approximately $6,484,422.

 

The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

 

James George Robinson also recently made the following trades:

 

  • On Friday, January 8th, James George Robinson bought 95,000 shares of Nymox Pharmaceutical Corp stock. The shares were purchased at an average price of $2.90 per share, for a total transaction of $275,500.00.
  • On Wednesday, December 30th, James George Robinson bought 5,000 shares of Nymox Pharmaceutical Corp stock. The shares were purchased at an average price of $3.38 per share, for a total transaction of $16,900.00.

 

 

Nymox Pharmaceutical Corporation.
 

Nymox, is a bio pharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia, and the treatment of low-grade localized prostate cancer.

 

The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also has a patent portfolio covering its marketed products, its investigatory drug, as well as other therapeutic and diagnostic indications.

 

The Company also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer’s disease. The Company’s subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex conducts research and development, and manufacturing for NicAlert and TobacAlert.